nodes	percent_of_prediction	percent_of_DWPC	metapath
Candesartan—CYP2C8—Nilutamide—prostate cancer	0.0644	0.106	CbGbCtD
Candesartan—CYP2C8—Abiraterone—prostate cancer	0.0533	0.0877	CbGbCtD
Candesartan—CYP2C9—Nilutamide—prostate cancer	0.0449	0.0738	CbGbCtD
Candesartan—CYP2C9—Bicalutamide—prostate cancer	0.0449	0.0738	CbGbCtD
Candesartan—ABCB1—Estramustine—prostate cancer	0.0405	0.0666	CbGbCtD
Candesartan—CYP2C8—Cabazitaxel—prostate cancer	0.0395	0.0649	CbGbCtD
Candesartan—CYP2C8—Ethinyl Estradiol—prostate cancer	0.0344	0.0565	CbGbCtD
Candesartan—CYP2C9—Estrone—prostate cancer	0.0269	0.0442	CbGbCtD
Candesartan—ABCB1—Cabazitaxel—prostate cancer	0.0267	0.0439	CbGbCtD
Candesartan—ABCB1—Estrone—prostate cancer	0.0261	0.0429	CbGbCtD
Candesartan—PTGS1—Etoposide—prostate cancer	0.0251	0.0412	CbGbCtD
Candesartan—ABCB1—Ethinyl Estradiol—prostate cancer	0.0233	0.0383	CbGbCtD
Candesartan—CYP2C8—Estradiol—prostate cancer	0.0221	0.0364	CbGbCtD
Candesartan—CYP2C9—Capecitabine—prostate cancer	0.0204	0.0335	CbGbCtD
Candesartan—ABCB1—Conjugated Estrogens—prostate cancer	0.0171	0.0281	CbGbCtD
Candesartan—ABCB1—Mitoxantrone—prostate cancer	0.0155	0.0255	CbGbCtD
Candesartan—CYP2C9—Estradiol—prostate cancer	0.0154	0.0254	CbGbCtD
Candesartan—ABCB1—Estradiol—prostate cancer	0.015	0.0247	CbGbCtD
Candesartan—CYP2C8—Etoposide—prostate cancer	0.0145	0.0238	CbGbCtD
Candesartan—ABCB1—Prednisone—prostate cancer	0.0129	0.0212	CbGbCtD
Candesartan—ABCB1—Etoposide—prostate cancer	0.00979	0.0161	CbGbCtD
Candesartan—ABCB1—Docetaxel—prostate cancer	0.00896	0.0147	CbGbCtD
Candesartan—ABCB1—Doxorubicin—prostate cancer	0.00668	0.011	CbGbCtD
Candesartan—Losartan—UGT2B17—prostate cancer	0.00279	0.529	CrCbGaD
Candesartan—CYP2C9—urine—prostate cancer	0.00144	0.163	CbGeAlD
Candesartan—AGTR1—prostate gland—prostate cancer	0.00107	0.121	CbGeAlD
Candesartan—AGTR1—epithelium—prostate cancer	0.000788	0.0891	CbGeAlD
Candesartan—AGTR1—renal system—prostate cancer	0.000731	0.0826	CbGeAlD
Candesartan—Deferasirox—CYP3A4—prostate cancer	0.000506	0.0957	CrCbGaD
Candesartan—AGTR1—testis—prostate cancer	0.000473	0.0534	CbGeAlD
Candesartan—PTGS1—prostate gland—prostate cancer	0.000472	0.0533	CbGeAlD
Candesartan—PTGS1—seminal vesicle—prostate cancer	0.000399	0.0451	CbGeAlD
Candesartan—CYP2C8—renal system—prostate cancer	0.000396	0.0448	CbGeAlD
Candesartan—Telmisartan—CYP2C19—prostate cancer	0.000365	0.0691	CrCbGaD
Candesartan—PTGS1—epithelium—prostate cancer	0.000347	0.0392	CbGeAlD
Candesartan—AGTR1—lymph node—prostate cancer	0.000343	0.0387	CbGeAlD
Candesartan—PTGS1—renal system—prostate cancer	0.000321	0.0363	CbGeAlD
Candesartan—Pranlukast—CYP3A4—prostate cancer	0.000303	0.0573	CrCbGaD
Candesartan—Tasosartan—CYP3A4—prostate cancer	0.000285	0.0539	CrCbGaD
Candesartan—ABCB1—prostate gland—prostate cancer	0.000279	0.0315	CbGeAlD
Candesartan—Losartan—CYP3A5—prostate cancer	0.000279	0.0527	CrCbGaD
Candesartan—Losartan—ACE—prostate cancer	0.000257	0.0486	CrCbGaD
Candesartan—CYP2C8—testis—prostate cancer	0.000256	0.029	CbGeAlD
Candesartan—ABCB1—seminal vesicle—prostate cancer	0.000236	0.0267	CbGeAlD
Candesartan—PTGS1—testis—prostate cancer	0.000208	0.0235	CbGeAlD
Candesartan—ABCB1—epithelium—prostate cancer	0.000205	0.0232	CbGeAlD
Candesartan—ABCB1—renal system—prostate cancer	0.00019	0.0215	CbGeAlD
Candesartan—Losartan—CYP2C19—prostate cancer	0.00019	0.0359	CrCbGaD
Candesartan—Irbesartan—CYP3A4—prostate cancer	0.000187	0.0354	CrCbGaD
Candesartan—ABCB1—urethra—prostate cancer	0.000187	0.0211	CbGeAlD
Candesartan—PTGS1—lymph node—prostate cancer	0.000151	0.017	CbGeAlD
Candesartan—ABCB1—bone marrow—prostate cancer	0.000144	0.0162	CbGeAlD
Candesartan—Mental disorder—Capecitabine—prostate cancer	0.000129	0.000584	CcSEcCtD
Candesartan—Blood creatinine increased—Doxorubicin—prostate cancer	0.000129	0.000581	CcSEcCtD
Candesartan—Malnutrition—Capecitabine—prostate cancer	0.000128	0.00058	CcSEcCtD
Candesartan—Back pain—Docetaxel—prostate cancer	0.000128	0.000579	CcSEcCtD
Candesartan—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000128	0.000578	CcSEcCtD
Candesartan—Thrombocytopenia—Etoposide—prostate cancer	0.000127	0.000576	CcSEcCtD
Candesartan—Tachycardia—Etoposide—prostate cancer	0.000127	0.000574	CcSEcCtD
Candesartan—Nausea—Goserelin—prostate cancer	0.000126	0.000569	CcSEcCtD
Candesartan—Hyperhidrosis—Etoposide—prostate cancer	0.000126	0.000569	CcSEcCtD
Candesartan—Angina pectoris—Epirubicin—prostate cancer	0.000125	0.000565	CcSEcCtD
Candesartan—Nausea—Conjugated Estrogens—prostate cancer	0.000125	0.000563	CcSEcCtD
Candesartan—Urticaria—Mitoxantrone—prostate cancer	0.000124	0.000562	CcSEcCtD
Candesartan—Back pain—Capecitabine—prostate cancer	0.000124	0.000561	CcSEcCtD
Candesartan—Abdominal pain—Mitoxantrone—prostate cancer	0.000124	0.000559	CcSEcCtD
Candesartan—Body temperature increased—Mitoxantrone—prostate cancer	0.000124	0.000559	CcSEcCtD
Candesartan—Bronchitis—Epirubicin—prostate cancer	0.000123	0.000558	CcSEcCtD
Candesartan—ABCB1—testis—prostate cancer	0.000123	0.0139	CbGeAlD
Candesartan—Anaemia—Docetaxel—prostate cancer	0.000123	0.000553	CcSEcCtD
Candesartan—Hypotension—Etoposide—prostate cancer	0.000122	0.00055	CcSEcCtD
Candesartan—Losartan—CYP3A4—prostate cancer	0.000121	0.0228	CrCbGaD
Candesartan—Asthenia—Estradiol—prostate cancer	0.000121	0.000544	CcSEcCtD
Candesartan—Neutropenia—Epirubicin—prostate cancer	0.00012	0.000542	CcSEcCtD
Candesartan—Upper respiratory tract infection—Epirubicin—prostate cancer	0.000119	0.000539	CcSEcCtD
Candesartan—Pruritus—Estradiol—prostate cancer	0.000119	0.000537	CcSEcCtD
Candesartan—Leukopenia—Docetaxel—prostate cancer	0.000119	0.000536	CcSEcCtD
Candesartan—Anaemia—Capecitabine—prostate cancer	0.000119	0.000536	CcSEcCtD
Candesartan—Palpitations—Docetaxel—prostate cancer	0.000117	0.000529	CcSEcCtD
Candesartan—Paraesthesia—Etoposide—prostate cancer	0.000117	0.000528	CcSEcCtD
Candesartan—Dyspnoea—Etoposide—prostate cancer	0.000116	0.000524	CcSEcCtD
Candesartan—Hyperglycaemia—Epirubicin—prostate cancer	0.000116	0.000523	CcSEcCtD
Candesartan—Somnolence—Etoposide—prostate cancer	0.000116	0.000523	CcSEcCtD
Candesartan—Cough—Docetaxel—prostate cancer	0.000116	0.000523	CcSEcCtD
Candesartan—Angina pectoris—Doxorubicin—prostate cancer	0.000116	0.000522	CcSEcCtD
Candesartan—Vertigo—Capecitabine—prostate cancer	0.000115	0.000521	CcSEcCtD
Candesartan—Mental disorder—Prednisone—prostate cancer	0.000115	0.00052	CcSEcCtD
Candesartan—Diarrhoea—Estradiol—prostate cancer	0.000115	0.000519	CcSEcCtD
Candesartan—Leukopenia—Capecitabine—prostate cancer	0.000115	0.000519	CcSEcCtD
Candesartan—Hypertension—Docetaxel—prostate cancer	0.000114	0.000517	CcSEcCtD
Candesartan—Malnutrition—Prednisone—prostate cancer	0.000114	0.000516	CcSEcCtD
Candesartan—Bronchitis—Doxorubicin—prostate cancer	0.000114	0.000516	CcSEcCtD
Candesartan—Palpitations—Capecitabine—prostate cancer	0.000113	0.000512	CcSEcCtD
Candesartan—Chest pain—Docetaxel—prostate cancer	0.000113	0.00051	CcSEcCtD
Candesartan—Arthralgia—Docetaxel—prostate cancer	0.000113	0.00051	CcSEcCtD
Candesartan—Myalgia—Docetaxel—prostate cancer	0.000113	0.00051	CcSEcCtD
Candesartan—Renal failure—Epirubicin—prostate cancer	0.000112	0.000508	CcSEcCtD
Candesartan—Gastrointestinal disorder—Etoposide—prostate cancer	0.000112	0.000508	CcSEcCtD
Candesartan—Asthenia—Mitoxantrone—prostate cancer	0.000112	0.000507	CcSEcCtD
Candesartan—Fatigue—Etoposide—prostate cancer	0.000112	0.000507	CcSEcCtD
Candesartan—Cough—Capecitabine—prostate cancer	0.000112	0.000506	CcSEcCtD
Candesartan—Dizziness—Estradiol—prostate cancer	0.000111	0.000502	CcSEcCtD
Candesartan—Neutropenia—Doxorubicin—prostate cancer	0.000111	0.000502	CcSEcCtD
Candesartan—Hypertension—Capecitabine—prostate cancer	0.000111	0.000501	CcSEcCtD
Candesartan—Upper respiratory tract infection—Doxorubicin—prostate cancer	0.00011	0.000499	CcSEcCtD
Candesartan—Arthralgia—Capecitabine—prostate cancer	0.000109	0.000494	CcSEcCtD
Candesartan—Myalgia—Capecitabine—prostate cancer	0.000109	0.000494	CcSEcCtD
Candesartan—Chest pain—Capecitabine—prostate cancer	0.000109	0.000494	CcSEcCtD
Candesartan—Haematuria—Epirubicin—prostate cancer	0.000109	0.000493	CcSEcCtD
Candesartan—Anxiety—Capecitabine—prostate cancer	0.000109	0.000492	CcSEcCtD
Candesartan—Epistaxis—Epirubicin—prostate cancer	0.000108	0.000488	CcSEcCtD
Candesartan—Sinusitis—Epirubicin—prostate cancer	0.000107	0.000485	CcSEcCtD
Candesartan—Hyperglycaemia—Doxorubicin—prostate cancer	0.000107	0.000484	CcSEcCtD
Candesartan—Diarrhoea—Mitoxantrone—prostate cancer	0.000107	0.000484	CcSEcCtD
Candesartan—Vomiting—Estradiol—prostate cancer	0.000107	0.000482	CcSEcCtD
Candesartan—Agranulocytosis—Epirubicin—prostate cancer	0.000107	0.000482	CcSEcCtD
Candesartan—Gastrointestinal pain—Etoposide—prostate cancer	0.000106	0.000481	CcSEcCtD
Candesartan—Thrombocytopenia—Docetaxel—prostate cancer	0.000106	0.000479	CcSEcCtD
Candesartan—Rash—Estradiol—prostate cancer	0.000106	0.000478	CcSEcCtD
Candesartan—Dermatitis—Estradiol—prostate cancer	0.000106	0.000478	CcSEcCtD
Candesartan—Anaemia—Prednisone—prostate cancer	0.000106	0.000477	CcSEcCtD
Candesartan—Tachycardia—Docetaxel—prostate cancer	0.000106	0.000477	CcSEcCtD
Candesartan—Headache—Estradiol—prostate cancer	0.000105	0.000475	CcSEcCtD
Candesartan—Angioedema—Prednisone—prostate cancer	0.000104	0.000472	CcSEcCtD
Candesartan—Renal failure—Doxorubicin—prostate cancer	0.000104	0.00047	CcSEcCtD
Candesartan—Urticaria—Etoposide—prostate cancer	0.000103	0.000467	CcSEcCtD
Candesartan—Haemoglobin—Epirubicin—prostate cancer	0.000103	0.000466	CcSEcCtD
Candesartan—Rhinitis—Epirubicin—prostate cancer	0.000103	0.000465	CcSEcCtD
Candesartan—Abdominal pain—Etoposide—prostate cancer	0.000103	0.000465	CcSEcCtD
Candesartan—Body temperature increased—Etoposide—prostate cancer	0.000103	0.000465	CcSEcCtD
Candesartan—Vertigo—Prednisone—prostate cancer	0.000103	0.000464	CcSEcCtD
Candesartan—Haemorrhage—Epirubicin—prostate cancer	0.000103	0.000464	CcSEcCtD
Candesartan—Hepatitis—Epirubicin—prostate cancer	0.000103	0.000464	CcSEcCtD
Candesartan—Thrombocytopenia—Capecitabine—prostate cancer	0.000103	0.000463	CcSEcCtD
Candesartan—Tachycardia—Capecitabine—prostate cancer	0.000102	0.000462	CcSEcCtD
Candesartan—Pharyngitis—Epirubicin—prostate cancer	0.000102	0.000461	CcSEcCtD
Candesartan—Urinary tract disorder—Epirubicin—prostate cancer	0.000101	0.000458	CcSEcCtD
Candesartan—Hyperhidrosis—Capecitabine—prostate cancer	0.000101	0.000457	CcSEcCtD
Candesartan—Oedema peripheral—Epirubicin—prostate cancer	0.000101	0.000457	CcSEcCtD
Candesartan—Hypotension—Docetaxel—prostate cancer	0.000101	0.000457	CcSEcCtD
Candesartan—Haematuria—Doxorubicin—prostate cancer	0.000101	0.000456	CcSEcCtD
Candesartan—Urethral disorder—Epirubicin—prostate cancer	0.000101	0.000455	CcSEcCtD
Candesartan—Epistaxis—Doxorubicin—prostate cancer	9.99e-05	0.000451	CcSEcCtD
Candesartan—Nausea—Estradiol—prostate cancer	9.98e-05	0.000451	CcSEcCtD
Candesartan—Vomiting—Mitoxantrone—prostate cancer	9.95e-05	0.00045	CcSEcCtD
Candesartan—Sinusitis—Doxorubicin—prostate cancer	9.93e-05	0.000449	CcSEcCtD
Candesartan—Agranulocytosis—Doxorubicin—prostate cancer	9.88e-05	0.000446	CcSEcCtD
Candesartan—Hypertension—Prednisone—prostate cancer	9.87e-05	0.000446	CcSEcCtD
Candesartan—Rash—Mitoxantrone—prostate cancer	9.87e-05	0.000446	CcSEcCtD
Candesartan—Dermatitis—Mitoxantrone—prostate cancer	9.86e-05	0.000445	CcSEcCtD
Candesartan—Musculoskeletal discomfort—Docetaxel—prostate cancer	9.86e-05	0.000445	CcSEcCtD
Candesartan—Headache—Mitoxantrone—prostate cancer	9.81e-05	0.000443	CcSEcCtD
Candesartan—Hypotension—Capecitabine—prostate cancer	9.79e-05	0.000442	CcSEcCtD
Candesartan—Arthralgia—Prednisone—prostate cancer	9.73e-05	0.00044	CcSEcCtD
Candesartan—Myalgia—Prednisone—prostate cancer	9.73e-05	0.00044	CcSEcCtD
Candesartan—Paraesthesia—Docetaxel—prostate cancer	9.72e-05	0.000439	CcSEcCtD
Candesartan—Anxiety—Prednisone—prostate cancer	9.7e-05	0.000438	CcSEcCtD
Candesartan—Dyspnoea—Docetaxel—prostate cancer	9.65e-05	0.000436	CcSEcCtD
Candesartan—Somnolence—Docetaxel—prostate cancer	9.62e-05	0.000434	CcSEcCtD
Candesartan—Haemoglobin—Doxorubicin—prostate cancer	9.55e-05	0.000432	CcSEcCtD
Candesartan—Musculoskeletal discomfort—Capecitabine—prostate cancer	9.54e-05	0.000431	CcSEcCtD
Candesartan—Rhinitis—Doxorubicin—prostate cancer	9.53e-05	0.00043	CcSEcCtD
Candesartan—Dyspepsia—Docetaxel—prostate cancer	9.52e-05	0.00043	CcSEcCtD
Candesartan—Hepatitis—Doxorubicin—prostate cancer	9.5e-05	0.000429	CcSEcCtD
Candesartan—Haemorrhage—Doxorubicin—prostate cancer	9.5e-05	0.000429	CcSEcCtD
Candesartan—Pharyngitis—Doxorubicin—prostate cancer	9.43e-05	0.000426	CcSEcCtD
Candesartan—Paraesthesia—Capecitabine—prostate cancer	9.41e-05	0.000425	CcSEcCtD
Candesartan—Urinary tract disorder—Doxorubicin—prostate cancer	9.39e-05	0.000424	CcSEcCtD
Candesartan—Oedema peripheral—Doxorubicin—prostate cancer	9.36e-05	0.000423	CcSEcCtD
Candesartan—Gastrointestinal disorder—Docetaxel—prostate cancer	9.34e-05	0.000422	CcSEcCtD
Candesartan—Asthenia—Etoposide—prostate cancer	9.34e-05	0.000422	CcSEcCtD
Candesartan—Dyspnoea—Capecitabine—prostate cancer	9.34e-05	0.000422	CcSEcCtD
Candesartan—Fatigue—Docetaxel—prostate cancer	9.33e-05	0.000421	CcSEcCtD
Candesartan—Urethral disorder—Doxorubicin—prostate cancer	9.32e-05	0.000421	CcSEcCtD
Candesartan—Nausea—Mitoxantrone—prostate cancer	9.3e-05	0.00042	CcSEcCtD
Candesartan—Dyspepsia—Capecitabine—prostate cancer	9.22e-05	0.000417	CcSEcCtD
Candesartan—Pruritus—Etoposide—prostate cancer	9.21e-05	0.000416	CcSEcCtD
Candesartan—Tachycardia—Prednisone—prostate cancer	9.11e-05	0.000411	CcSEcCtD
Candesartan—Gastrointestinal disorder—Capecitabine—prostate cancer	9.04e-05	0.000409	CcSEcCtD
Candesartan—Fatigue—Capecitabine—prostate cancer	9.03e-05	0.000408	CcSEcCtD
Candesartan—Hyperhidrosis—Prednisone—prostate cancer	9.02e-05	0.000407	CcSEcCtD
Candesartan—Mental disorder—Epirubicin—prostate cancer	9e-05	0.000407	CcSEcCtD
Candesartan—Malnutrition—Epirubicin—prostate cancer	8.94e-05	0.000404	CcSEcCtD
Candesartan—Diarrhoea—Etoposide—prostate cancer	8.91e-05	0.000402	CcSEcCtD
Candesartan—ABCB1—lymph node—prostate cancer	8.91e-05	0.0101	CbGeAlD
Candesartan—Gastrointestinal pain—Docetaxel—prostate cancer	8.85e-05	0.0004	CcSEcCtD
Candesartan—Back pain—Epirubicin—prostate cancer	8.65e-05	0.000391	CcSEcCtD
Candesartan—Dizziness—Etoposide—prostate cancer	8.61e-05	0.000389	CcSEcCtD
Candesartan—Gastrointestinal pain—Capecitabine—prostate cancer	8.57e-05	0.000387	CcSEcCtD
Candesartan—Abdominal pain—Docetaxel—prostate cancer	8.55e-05	0.000386	CcSEcCtD
Candesartan—Body temperature increased—Docetaxel—prostate cancer	8.55e-05	0.000386	CcSEcCtD
Candesartan—Musculoskeletal discomfort—Prednisone—prostate cancer	8.5e-05	0.000384	CcSEcCtD
Candesartan—Paraesthesia—Prednisone—prostate cancer	8.38e-05	0.000378	CcSEcCtD
Candesartan—Mental disorder—Doxorubicin—prostate cancer	8.33e-05	0.000376	CcSEcCtD
Candesartan—Urticaria—Capecitabine—prostate cancer	8.32e-05	0.000376	CcSEcCtD
Candesartan—Abdominal pain—Capecitabine—prostate cancer	8.28e-05	0.000374	CcSEcCtD
Candesartan—Body temperature increased—Capecitabine—prostate cancer	8.28e-05	0.000374	CcSEcCtD
Candesartan—Vomiting—Etoposide—prostate cancer	8.28e-05	0.000374	CcSEcCtD
Candesartan—Malnutrition—Doxorubicin—prostate cancer	8.27e-05	0.000374	CcSEcCtD
Candesartan—Anaemia—Epirubicin—prostate cancer	8.26e-05	0.000373	CcSEcCtD
Candesartan—Dyspepsia—Prednisone—prostate cancer	8.21e-05	0.000371	CcSEcCtD
Candesartan—Rash—Etoposide—prostate cancer	8.21e-05	0.000371	CcSEcCtD
Candesartan—Dermatitis—Etoposide—prostate cancer	8.2e-05	0.00037	CcSEcCtD
Candesartan—Headache—Etoposide—prostate cancer	8.16e-05	0.000368	CcSEcCtD
Candesartan—Fatigue—Prednisone—prostate cancer	8.05e-05	0.000363	CcSEcCtD
Candesartan—Vertigo—Epirubicin—prostate cancer	8.03e-05	0.000363	CcSEcCtD
Candesartan—Leukopenia—Epirubicin—prostate cancer	8e-05	0.000362	CcSEcCtD
Candesartan—Back pain—Doxorubicin—prostate cancer	8e-05	0.000362	CcSEcCtD
Candesartan—Palpitations—Epirubicin—prostate cancer	7.9e-05	0.000357	CcSEcCtD
Candesartan—Cough—Epirubicin—prostate cancer	7.8e-05	0.000352	CcSEcCtD
Candesartan—Asthenia—Docetaxel—prostate cancer	7.76e-05	0.000351	CcSEcCtD
Candesartan—Nausea—Etoposide—prostate cancer	7.73e-05	0.000349	CcSEcCtD
Candesartan—Hypertension—Epirubicin—prostate cancer	7.72e-05	0.000349	CcSEcCtD
Candesartan—Pruritus—Docetaxel—prostate cancer	7.66e-05	0.000346	CcSEcCtD
Candesartan—Anaemia—Doxorubicin—prostate cancer	7.65e-05	0.000345	CcSEcCtD
Candesartan—Gastrointestinal pain—Prednisone—prostate cancer	7.63e-05	0.000345	CcSEcCtD
Candesartan—Myalgia—Epirubicin—prostate cancer	7.61e-05	0.000344	CcSEcCtD
Candesartan—Chest pain—Epirubicin—prostate cancer	7.61e-05	0.000344	CcSEcCtD
Candesartan—Arthralgia—Epirubicin—prostate cancer	7.61e-05	0.000344	CcSEcCtD
Candesartan—Anxiety—Epirubicin—prostate cancer	7.59e-05	0.000343	CcSEcCtD
Candesartan—Asthenia—Capecitabine—prostate cancer	7.52e-05	0.00034	CcSEcCtD
Candesartan—Vertigo—Doxorubicin—prostate cancer	7.43e-05	0.000336	CcSEcCtD
Candesartan—Urticaria—Prednisone—prostate cancer	7.41e-05	0.000335	CcSEcCtD
Candesartan—Pruritus—Capecitabine—prostate cancer	7.41e-05	0.000335	CcSEcCtD
Candesartan—Leukopenia—Doxorubicin—prostate cancer	7.41e-05	0.000335	CcSEcCtD
Candesartan—Diarrhoea—Docetaxel—prostate cancer	7.4e-05	0.000334	CcSEcCtD
Candesartan—Body temperature increased—Prednisone—prostate cancer	7.38e-05	0.000333	CcSEcCtD
Candesartan—Abdominal pain—Prednisone—prostate cancer	7.38e-05	0.000333	CcSEcCtD
Candesartan—Palpitations—Doxorubicin—prostate cancer	7.31e-05	0.00033	CcSEcCtD
Candesartan—Cough—Doxorubicin—prostate cancer	7.22e-05	0.000326	CcSEcCtD
Candesartan—Diarrhoea—Capecitabine—prostate cancer	7.17e-05	0.000324	CcSEcCtD
Candesartan—Dizziness—Docetaxel—prostate cancer	7.15e-05	0.000323	CcSEcCtD
Candesartan—Thrombocytopenia—Epirubicin—prostate cancer	7.15e-05	0.000323	CcSEcCtD
Candesartan—Hypertension—Doxorubicin—prostate cancer	7.14e-05	0.000323	CcSEcCtD
Candesartan—Tachycardia—Epirubicin—prostate cancer	7.12e-05	0.000322	CcSEcCtD
Candesartan—Hyperhidrosis—Epirubicin—prostate cancer	7.06e-05	0.000319	CcSEcCtD
Candesartan—Myalgia—Doxorubicin—prostate cancer	7.04e-05	0.000318	CcSEcCtD
Candesartan—Chest pain—Doxorubicin—prostate cancer	7.04e-05	0.000318	CcSEcCtD
Candesartan—Arthralgia—Doxorubicin—prostate cancer	7.04e-05	0.000318	CcSEcCtD
Candesartan—Anxiety—Doxorubicin—prostate cancer	7.02e-05	0.000317	CcSEcCtD
Candesartan—Dizziness—Capecitabine—prostate cancer	6.93e-05	0.000313	CcSEcCtD
Candesartan—Vomiting—Docetaxel—prostate cancer	6.88e-05	0.000311	CcSEcCtD
Candesartan—Rash—Docetaxel—prostate cancer	6.82e-05	0.000308	CcSEcCtD
Candesartan—Hypotension—Epirubicin—prostate cancer	6.82e-05	0.000308	CcSEcCtD
Candesartan—Dermatitis—Docetaxel—prostate cancer	6.82e-05	0.000308	CcSEcCtD
Candesartan—Headache—Docetaxel—prostate cancer	6.78e-05	0.000306	CcSEcCtD
Candesartan—Asthenia—Prednisone—prostate cancer	6.69e-05	0.000302	CcSEcCtD
Candesartan—Vomiting—Capecitabine—prostate cancer	6.66e-05	0.000301	CcSEcCtD
Candesartan—Musculoskeletal discomfort—Epirubicin—prostate cancer	6.65e-05	0.0003	CcSEcCtD
Candesartan—Thrombocytopenia—Doxorubicin—prostate cancer	6.61e-05	0.000299	CcSEcCtD
Candesartan—Rash—Capecitabine—prostate cancer	6.61e-05	0.000298	CcSEcCtD
Candesartan—Pruritus—Prednisone—prostate cancer	6.6e-05	0.000298	CcSEcCtD
Candesartan—Dermatitis—Capecitabine—prostate cancer	6.6e-05	0.000298	CcSEcCtD
Candesartan—Tachycardia—Doxorubicin—prostate cancer	6.59e-05	0.000298	CcSEcCtD
Candesartan—Headache—Capecitabine—prostate cancer	6.56e-05	0.000296	CcSEcCtD
Candesartan—Paraesthesia—Epirubicin—prostate cancer	6.55e-05	0.000296	CcSEcCtD
Candesartan—Hyperhidrosis—Doxorubicin—prostate cancer	6.53e-05	0.000295	CcSEcCtD
Candesartan—Dyspnoea—Epirubicin—prostate cancer	6.51e-05	0.000294	CcSEcCtD
Candesartan—Somnolence—Epirubicin—prostate cancer	6.49e-05	0.000293	CcSEcCtD
Candesartan—Nausea—Docetaxel—prostate cancer	6.43e-05	0.00029	CcSEcCtD
Candesartan—Dyspepsia—Epirubicin—prostate cancer	6.42e-05	0.00029	CcSEcCtD
Candesartan—Diarrhoea—Prednisone—prostate cancer	6.38e-05	0.000288	CcSEcCtD
Candesartan—Hypotension—Doxorubicin—prostate cancer	6.31e-05	0.000285	CcSEcCtD
Candesartan—Gastrointestinal disorder—Epirubicin—prostate cancer	6.3e-05	0.000285	CcSEcCtD
Candesartan—Fatigue—Epirubicin—prostate cancer	6.29e-05	0.000284	CcSEcCtD
Candesartan—Nausea—Capecitabine—prostate cancer	6.22e-05	0.000281	CcSEcCtD
Candesartan—Dizziness—Prednisone—prostate cancer	6.17e-05	0.000279	CcSEcCtD
Candesartan—Musculoskeletal discomfort—Doxorubicin—prostate cancer	6.15e-05	0.000278	CcSEcCtD
Candesartan—Paraesthesia—Doxorubicin—prostate cancer	6.06e-05	0.000274	CcSEcCtD
Candesartan—Dyspnoea—Doxorubicin—prostate cancer	6.02e-05	0.000272	CcSEcCtD
Candesartan—Somnolence—Doxorubicin—prostate cancer	6e-05	0.000271	CcSEcCtD
Candesartan—Gastrointestinal pain—Epirubicin—prostate cancer	5.97e-05	0.00027	CcSEcCtD
Candesartan—Dyspepsia—Doxorubicin—prostate cancer	5.94e-05	0.000268	CcSEcCtD
Candesartan—Vomiting—Prednisone—prostate cancer	5.93e-05	0.000268	CcSEcCtD
Candesartan—Rash—Prednisone—prostate cancer	5.88e-05	0.000266	CcSEcCtD
Candesartan—Dermatitis—Prednisone—prostate cancer	5.88e-05	0.000266	CcSEcCtD
Candesartan—Headache—Prednisone—prostate cancer	5.85e-05	0.000264	CcSEcCtD
Candesartan—Gastrointestinal disorder—Doxorubicin—prostate cancer	5.83e-05	0.000263	CcSEcCtD
Candesartan—Fatigue—Doxorubicin—prostate cancer	5.82e-05	0.000263	CcSEcCtD
Candesartan—Urticaria—Epirubicin—prostate cancer	5.8e-05	0.000262	CcSEcCtD
Candesartan—Abdominal pain—Epirubicin—prostate cancer	5.77e-05	0.000261	CcSEcCtD
Candesartan—Body temperature increased—Epirubicin—prostate cancer	5.77e-05	0.000261	CcSEcCtD
Candesartan—Nausea—Prednisone—prostate cancer	5.54e-05	0.00025	CcSEcCtD
Candesartan—Gastrointestinal pain—Doxorubicin—prostate cancer	5.52e-05	0.000249	CcSEcCtD
Candesartan—Urticaria—Doxorubicin—prostate cancer	5.36e-05	0.000242	CcSEcCtD
Candesartan—Abdominal pain—Doxorubicin—prostate cancer	5.34e-05	0.000241	CcSEcCtD
Candesartan—Body temperature increased—Doxorubicin—prostate cancer	5.34e-05	0.000241	CcSEcCtD
Candesartan—Asthenia—Epirubicin—prostate cancer	5.24e-05	0.000237	CcSEcCtD
Candesartan—Pruritus—Epirubicin—prostate cancer	5.16e-05	0.000233	CcSEcCtD
Candesartan—Diarrhoea—Epirubicin—prostate cancer	4.99e-05	0.000226	CcSEcCtD
Candesartan—Asthenia—Doxorubicin—prostate cancer	4.84e-05	0.000219	CcSEcCtD
Candesartan—Dizziness—Epirubicin—prostate cancer	4.83e-05	0.000218	CcSEcCtD
Candesartan—Pruritus—Doxorubicin—prostate cancer	4.78e-05	0.000216	CcSEcCtD
Candesartan—Vomiting—Epirubicin—prostate cancer	4.64e-05	0.00021	CcSEcCtD
Candesartan—Diarrhoea—Doxorubicin—prostate cancer	4.62e-05	0.000209	CcSEcCtD
Candesartan—Rash—Epirubicin—prostate cancer	4.6e-05	0.000208	CcSEcCtD
Candesartan—Dermatitis—Epirubicin—prostate cancer	4.6e-05	0.000208	CcSEcCtD
Candesartan—Headache—Epirubicin—prostate cancer	4.57e-05	0.000207	CcSEcCtD
Candesartan—Dizziness—Doxorubicin—prostate cancer	4.47e-05	0.000202	CcSEcCtD
Candesartan—Nausea—Epirubicin—prostate cancer	4.33e-05	0.000196	CcSEcCtD
Candesartan—Vomiting—Doxorubicin—prostate cancer	4.29e-05	0.000194	CcSEcCtD
Candesartan—Rash—Doxorubicin—prostate cancer	4.26e-05	0.000192	CcSEcCtD
Candesartan—Dermatitis—Doxorubicin—prostate cancer	4.25e-05	0.000192	CcSEcCtD
Candesartan—Headache—Doxorubicin—prostate cancer	4.23e-05	0.000191	CcSEcCtD
Candesartan—Nausea—Doxorubicin—prostate cancer	4.01e-05	0.000181	CcSEcCtD
Candesartan—ABCB1—Metabolism—GSTO1—prostate cancer	9.48e-06	6.06e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—HSD3B2—prostate cancer	9.48e-06	6.06e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—NAT2—prostate cancer	9.48e-06	6.06e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—GNG5—prostate cancer	9.46e-06	6.05e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—RXRA—prostate cancer	9.44e-06	6.04e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—INS—prostate cancer	9.37e-06	6e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	9.31e-06	5.95e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—GSTA2—prostate cancer	9.28e-06	5.94e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	9.18e-06	5.87e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—CREBBP—prostate cancer	9.18e-06	5.87e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—SULT1A1—prostate cancer	9.17e-06	5.86e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—ABCG5—prostate cancer	9.17e-06	5.86e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—NCOA3—prostate cancer	9.12e-06	5.83e-05	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—NOS3—prostate cancer	9.1e-06	5.82e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—COMT—prostate cancer	9.1e-06	5.82e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—PLCB2—prostate cancer	9.09e-06	5.81e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—CYP2C18—prostate cancer	9.09e-06	5.81e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—LRP2—prostate cancer	9.09e-06	5.81e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—IGF1—prostate cancer	9.07e-06	5.8e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—GSTP1—prostate cancer	9.05e-06	5.79e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—EGFR—prostate cancer	9.02e-06	5.77e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	8.96e-06	5.73e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—GSTA1—prostate cancer	8.95e-06	5.73e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—P4HB—prostate cancer	8.91e-06	5.7e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—ITPR1—prostate cancer	8.91e-06	5.7e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—NAT2—prostate cancer	8.85e-06	5.66e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—GSTO1—prostate cancer	8.85e-06	5.66e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—HSD3B2—prostate cancer	8.85e-06	5.66e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—MAP2K1—prostate cancer	8.76e-06	5.6e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism of lipids and lipoproteins—EP300—prostate cancer	8.76e-06	5.6e-05	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—prostate cancer	8.73e-06	5.58e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—PIK3CD—prostate cancer	8.71e-06	5.57e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—HPGDS—prostate cancer	8.7e-06	5.56e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—SLC22A1—prostate cancer	8.67e-06	5.54e-05	CbGpPWpGaD
Candesartan—ABCB1—Transmembrane transport of small molecules—PPARA—prostate cancer	8.67e-06	5.54e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—CYP2C19—prostate cancer	8.64e-06	5.53e-05	CbGpPWpGaD
Candesartan—AGTR1—GPCR downstream signaling—PIK3CA—prostate cancer	8.62e-06	5.52e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—SERPINE1—prostate cancer	8.61e-06	5.51e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—KRAS—prostate cancer	8.52e-06	5.45e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	8.51e-06	5.45e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—PLCB2—prostate cancer	8.49e-06	5.43e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—CYP2C18—prostate cancer	8.49e-06	5.43e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—LRP2—prostate cancer	8.49e-06	5.43e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—SULT2A1—prostate cancer	8.45e-06	5.4e-05	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—prostate cancer	8.45e-06	5.4e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—GSTT1—prostate cancer	8.44e-06	5.4e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—ACHE—prostate cancer	8.44e-06	5.4e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—TYMS—prostate cancer	8.42e-06	5.38e-05	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—PIK3CB—prostate cancer	8.4e-06	5.37e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—CYP2A6—prostate cancer	8.34e-06	5.33e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—FGF2—prostate cancer	8.34e-06	5.33e-05	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—PTGS2—prostate cancer	8.33e-06	5.32e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—P4HB—prostate cancer	8.33e-06	5.32e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—GSTM1—prostate cancer	8.32e-06	5.32e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—MED12—prostate cancer	8.31e-06	5.32e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	8.31e-06	5.31e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—GNG5—prostate cancer	8.25e-06	5.27e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—NOS3—prostate cancer	8.22e-06	5.26e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—LPL—prostate cancer	8.17e-06	5.22e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—AKR1C3—prostate cancer	8.11e-06	5.19e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—SLC22A1—prostate cancer	8.1e-06	5.18e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—PRKACB—prostate cancer	8.07e-06	5.16e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	8.01e-06	5.12e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—JAK2—prostate cancer	7.99e-06	5.11e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—CYP17A1—prostate cancer	7.99e-06	5.11e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—NCOA3—prostate cancer	7.94e-06	5.08e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—SULT2A1—prostate cancer	7.89e-06	5.05e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—CYP1A1—prostate cancer	7.89e-06	5.04e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	7.88e-06	5.04e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—PIK3CA—prostate cancer	7.83e-06	5.01e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—ERCC2—prostate cancer	7.82e-06	5e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—MDM2—prostate cancer	7.8e-06	4.99e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—MED12—prostate cancer	7.76e-06	4.97e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—GNG5—prostate cancer	7.7e-06	4.93e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—ERBB2—prostate cancer	7.69e-06	4.92e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—NCOA2—prostate cancer	7.61e-06	4.87e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—PIK3CB—prostate cancer	7.59e-06	4.85e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—HPGDS—prostate cancer	7.58e-06	4.85e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—CYP2C19—prostate cancer	7.53e-06	4.82e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—NCOA3—prostate cancer	7.42e-06	4.75e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—MTHFR—prostate cancer	7.35e-06	4.7e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—GSTT1—prostate cancer	7.35e-06	4.7e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—ACHE—prostate cancer	7.35e-06	4.7e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—CXCL8—prostate cancer	7.29e-06	4.66e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	7.29e-06	4.66e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—CYP2A6—prostate cancer	7.26e-06	4.65e-05	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—PTEN—prostate cancer	7.26e-06	4.64e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—SLC5A5—prostate cancer	7.26e-06	4.64e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—PPARA—prostate cancer	7.21e-06	4.61e-05	CbGpPWpGaD
Candesartan—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	7.13e-06	4.56e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—CDKN1B—prostate cancer	7.12e-06	4.55e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—CYP2E1—prostate cancer	7.09e-06	4.53e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—HPGDS—prostate cancer	7.08e-06	4.53e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—AKR1C3—prostate cancer	7.07e-06	4.52e-05	CbGpPWpGaD
Candesartan—AGTR1—GPCR downstream signaling—AKT1—prostate cancer	7.04e-06	4.51e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—CYP2C19—prostate cancer	7.03e-06	4.5e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—PRKACB—prostate cancer	7.03e-06	4.5e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—NQO1—prostate cancer	7.01e-06	4.48e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—CASP3—prostate cancer	6.98e-06	4.46e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—IL2—prostate cancer	6.97e-06	4.46e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—CYP17A1—prostate cancer	6.96e-06	4.45e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—IL6—prostate cancer	6.93e-06	4.43e-05	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—EP300—prostate cancer	6.92e-06	4.43e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—TH—prostate cancer	6.91e-06	4.42e-05	CbGpPWpGaD
Candesartan—ABCB1—Transmembrane transport of small molecules—CREBBP—prostate cancer	6.88e-06	4.4e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—GSTT1—prostate cancer	6.87e-06	4.39e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—ACHE—prostate cancer	6.87e-06	4.39e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	6.86e-06	4.39e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—CYP3A4—prostate cancer	6.84e-06	4.37e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	6.8e-06	4.35e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—CCND1—prostate cancer	6.79e-06	4.34e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—CYP2A6—prostate cancer	6.79e-06	4.34e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—CAV1—prostate cancer	6.78e-06	4.34e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	6.76e-06	4.32e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—CTNNB1—prostate cancer	6.73e-06	4.3e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—CYP1B1—prostate cancer	6.72e-06	4.3e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—NCOA2—prostate cancer	6.63e-06	4.24e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—AKR1C3—prostate cancer	6.6e-06	4.22e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—MMP9—prostate cancer	6.6e-06	4.22e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—CDKN1A—prostate cancer	6.57e-06	4.2e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—PRKACB—prostate cancer	6.57e-06	4.2e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—PTEN—prostate cancer	6.56e-06	4.19e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—GGT1—prostate cancer	6.51e-06	4.16e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—CYP17A1—prostate cancer	6.5e-06	4.16e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	6.48e-06	4.14e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—NCOA1—prostate cancer	6.41e-06	4.1e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	6.41e-06	4.1e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling by GPCR—AKT1—prostate cancer	6.4e-06	4.09e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—SLC5A5—prostate cancer	6.32e-06	4.04e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—CYP19A1—prostate cancer	6.32e-06	4.04e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—EP300—prostate cancer	6.25e-06	4e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—NCOA2—prostate cancer	6.19e-06	3.96e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—CYP2E1—prostate cancer	6.18e-06	3.95e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—PIK3CG—prostate cancer	6.18e-06	3.95e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—NQO1—prostate cancer	6.11e-06	3.91e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—RXRA—prostate cancer	6.1e-06	3.9e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—SRC—prostate cancer	6.08e-06	3.89e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—TH—prostate cancer	6.02e-06	3.85e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—CYP3A4—prostate cancer	5.96e-06	3.81e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	5.93e-06	3.79e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—VEGFA—prostate cancer	5.92e-06	3.79e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—SLC5A5—prostate cancer	5.91e-06	3.78e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—COMT—prostate cancer	5.88e-06	3.76e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—STAT3—prostate cancer	5.86e-06	3.75e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—CYP1B1—prostate cancer	5.86e-06	3.74e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—GSTP1—prostate cancer	5.85e-06	3.74e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—INS—prostate cancer	5.85e-06	3.74e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—CYP2E1—prostate cancer	5.77e-06	3.69e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—ITPR1—prostate cancer	5.75e-06	3.68e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—CREBBP—prostate cancer	5.73e-06	3.66e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—NQO1—prostate cancer	5.71e-06	3.65e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—GGT1—prostate cancer	5.67e-06	3.63e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—EP300—prostate cancer	5.66e-06	3.62e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—TH—prostate cancer	5.62e-06	3.6e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	5.59e-06	3.57e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—NCOA1—prostate cancer	5.59e-06	3.57e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—CYP3A4—prostate cancer	5.56e-06	3.56e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	5.54e-06	3.54e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—CYP19A1—prostate cancer	5.51e-06	3.52e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—CYP1B1—prostate cancer	5.47e-06	3.5e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—MYC—prostate cancer	5.45e-06	3.49e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—TGFB1—prostate cancer	5.44e-06	3.48e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—TYMS—prostate cancer	5.44e-06	3.48e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—PIK3CD—prostate cancer	5.43e-06	3.47e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—GSTM1—prostate cancer	5.37e-06	3.44e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—EGFR—prostate cancer	5.33e-06	3.41e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—RXRA—prostate cancer	5.31e-06	3.4e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—GGT1—prostate cancer	5.3e-06	3.39e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—LPL—prostate cancer	5.27e-06	3.37e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—NCOA1—prostate cancer	5.22e-06	3.34e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—CYP19A1—prostate cancer	5.14e-06	3.29e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—NOS3—prostate cancer	5.13e-06	3.28e-05	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—PIK3CA—prostate cancer	5.12e-06	3.28e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—COMT—prostate cancer	5.12e-06	3.27e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—GSTP1—prostate cancer	5.09e-06	3.26e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—CYP1A1—prostate cancer	5.09e-06	3.26e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—ERCC2—prostate cancer	5.05e-06	3.23e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—KRAS—prostate cancer	5.04e-06	3.22e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—ITPR1—prostate cancer	5.01e-06	3.21e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—RXRA—prostate cancer	4.96e-06	3.17e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	4.83e-06	3.09e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—COMT—prostate cancer	4.78e-06	3.06e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—GSTP1—prostate cancer	4.76e-06	3.04e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—MTHFR—prostate cancer	4.75e-06	3.04e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—TYMS—prostate cancer	4.74e-06	3.03e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—PIK3CB—prostate cancer	4.73e-06	3.03e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—PTGS2—prostate cancer	4.69e-06	3e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—ITPR1—prostate cancer	4.68e-06	2.99e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—GSTM1—prostate cancer	4.68e-06	2.99e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—PPARA—prostate cancer	4.66e-06	2.98e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—PIK3CA—prostate cancer	4.63e-06	2.96e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	4.6e-06	2.94e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—LPL—prostate cancer	4.59e-06	2.94e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—TP53—prostate cancer	4.48e-06	2.86e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—CYP1A1—prostate cancer	4.44e-06	2.84e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—TYMS—prostate cancer	4.42e-06	2.83e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—ERCC2—prostate cancer	4.4e-06	2.81e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—CAV1—prostate cancer	4.38e-06	2.8e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—GSTM1—prostate cancer	4.37e-06	2.8e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—LPL—prostate cancer	4.29e-06	2.75e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.18e-06	2.68e-05	CbGpPWpGaD
Candesartan—UGT1A3—Metabolism—AKT1—prostate cancer	4.18e-06	2.68e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—CYP1A1—prostate cancer	4.15e-06	2.65e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—MTHFR—prostate cancer	4.14e-06	2.65e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—ERCC2—prostate cancer	4.11e-06	2.63e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—IL6—prostate cancer	4.1e-06	2.62e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—PTEN—prostate cancer	4.09e-06	2.62e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—PPARA—prostate cancer	4.06e-06	2.6e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—PIK3CG—prostate cancer	3.99e-06	2.55e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—EP300—prostate cancer	3.9e-06	2.49e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—MTHFR—prostate cancer	3.86e-06	2.47e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—CAV1—prostate cancer	3.82e-06	2.44e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—PPARA—prostate cancer	3.79e-06	2.42e-05	CbGpPWpGaD
Candesartan—AGTR1—Signaling Pathways—AKT1—prostate cancer	3.78e-06	2.42e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—INS—prostate cancer	3.78e-06	2.42e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—CREBBP—prostate cancer	3.7e-06	2.37e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—CAV1—prostate cancer	3.57e-06	2.28e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—PIK3CD—prostate cancer	3.51e-06	2.24e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—PIK3CG—prostate cancer	3.48e-06	2.22e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.41e-06	2.18e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—NOS3—prostate cancer	3.31e-06	2.12e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—INS—prostate cancer	3.29e-06	2.1e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—PIK3CG—prostate cancer	3.25e-06	2.08e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—CREBBP—prostate cancer	3.22e-06	2.06e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—INS—prostate cancer	3.07e-06	1.97e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—PIK3CB—prostate cancer	3.06e-06	1.96e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—PIK3CD—prostate cancer	3.06e-06	1.95e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—PTGS2—prostate cancer	3.03e-06	1.94e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—CREBBP—prostate cancer	3.01e-06	1.93e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—NOS3—prostate cancer	2.89e-06	1.85e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—PIK3CA—prostate cancer	2.89e-06	1.85e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—PIK3CD—prostate cancer	2.85e-06	1.83e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—NOS3—prostate cancer	2.7e-06	1.72e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—PIK3CB—prostate cancer	2.66e-06	1.7e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—PTEN—prostate cancer	2.64e-06	1.69e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—PTGS2—prostate cancer	2.64e-06	1.69e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—EP300—prostate cancer	2.52e-06	1.61e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—PIK3CB—prostate cancer	2.49e-06	1.59e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—PTGS2—prostate cancer	2.47e-06	1.58e-05	CbGpPWpGaD
Candesartan—PTGS1—Metabolism—AKT1—prostate cancer	2.36e-06	1.51e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—PTEN—prostate cancer	2.3e-06	1.47e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—EP300—prostate cancer	2.19e-06	1.4e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—PTEN—prostate cancer	2.15e-06	1.38e-05	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—EP300—prostate cancer	2.05e-06	1.31e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—PIK3CA—prostate cancer	1.86e-06	1.19e-05	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—PIK3CA—prostate cancer	1.62e-06	1.04e-05	CbGpPWpGaD
Candesartan—CYP2C8—Metabolism—AKT1—prostate cancer	1.52e-06	9.74e-06	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—PIK3CA—prostate cancer	1.52e-06	9.7e-06	CbGpPWpGaD
Candesartan—ABCB1—Metabolism—AKT1—prostate cancer	1.33e-06	8.48e-06	CbGpPWpGaD
Candesartan—CYP2C9—Metabolism—AKT1—prostate cancer	1.24e-06	7.92e-06	CbGpPWpGaD
